ELV Stock Analysis — AI Buy/Sell Signals & Forecast
Real-time AI-powered analysis for ELV with price targets, technical indicators (RSI, MACD, SMA), institutional money flow, and news-based signals.
Unlock Full Pro Analysis
Real-time alerts, price targets, institutional flow & more — one-time $19.95.
ELV · Elevance Health, Inc.
Free summary — full analysis below.
Elevance Health, Inc.
Pre-Market & After Hours is Pro Only
Upgrade to unlock this and all premium features
Oct 8, 06:20 AM
Confidence Score is Pro Only
Upgrade to unlock this and all premium features
Optimal Buy & Sell Zones is Pro Only
Upgrade to unlock this and all premium features
Strong Uptrend — Price above SMA50 & SMA200, Golden Cross
Total Conviction Scorecard is Pro Only
Upgrade to unlock this and all premium features
Optimal Buy & Sell Zones is Pro Only
Upgrade to unlock this and all premium features
$-31.93 (-7.3%) from high
Day's Range: $400.19 – $410.54
+$129.47 (+47.1%) above low
▲ Above — short-term uptrend (bullish)
▲ Above — long-term uptrend (bullish)
✓ 0.7x avg — normal activity, signals are reliable
✓ Normal — healthy trading conditions
RSI, MACD & SMA based on daily closes — update at market close. Live price shown separately.
Institutional Money Flow is Pro Only
Upgrade to unlock this and all premium features
Phantom Flow is Pro Only
Upgrade to unlock this and all premium features
Smart Money Flow Index is Pro Only
Upgrade to unlock this and all premium features
Risk Score is Pro Only
Upgrade to unlock this and all premium features
Analyst ratings remain mixed with conflicting price target adjustments ahead of the upcoming third-quarter earnings report. Investors should wait for the October 21 conference call to gain clarity on the company's financial trajectory before making a move.
Latest News & Market Impact
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
UnitedHealth Q3 Coming Up: Two Questions Investors Can't Ignore
Barclays Adjusts Elevance Health Price Target to $469 From $457, Maintains Overweight Rating
ELV or DHR: Which Is the Better Value Stock Right Now?
Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
Disclaimer: This analysis is AI-generated and should not be considered financial advice. Always consult a qualified financial advisor before making investment decisions.
ELV Stock Analysis — Frequently Asked Questions
Is ELV a buy or sell right now?▾
Our AI engine analyzes ELV across technicals (RSI, MACD, SMA50/200), institutional money flow (OBV, SEC 13D/13G filings), news sentiment, and price action to produce a real-time buy/sell signal with a confidence score. The recommendation updates every time the analysis runs.
What is the price target for ELV?▾
The analysis calculates optimal entry and exit price targets for ELV using support/resistance levels, moving-average structure, and momentum. These levels are dynamic and recompute as new market data arrives.
What do the RSI and MACD signals say about ELV?▾
RSI measures whether ELV is overbought or oversold; MACD shows momentum and trend shifts. A bullish MACD crossover with RSI below 70 often signals continued upside, while divergence can warn of a reversal.
Are institutions buying ELV?▾
We track institutional positioning in ELV through On-Balance Volume (OBV) money flow and SEC Schedule 13D/13G filings — the same disclosures activist investors and large funds must file. Rising OBV plus new 13D filings typically indicate smart-money accumulation.
What are the main risks of investing in ELV?▾
Key risks for ELV include valuation compression, sector rotation, earnings volatility, and macro factors such as rates and inflation. The analysis grades risk from very low to very high based on volatility, drawdown history, and beta.
How accurate is the ELV AI analysis?▾
The ELV analysis combines real-time market data, technical indicators, institutional flow, and news-based sentiment. It is a decision-support tool, not financial advice — always do your own research and consider your risk tolerance before investing.
Market Intelligence provides AI-powered stock & ETF analysis for informational purposes only and does not constitute financial advice.